641
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Genetic Polymorphisms of Matrix Metalloproteinases 1–3 and Their Inhibitor are Not Associated With Premature Labor

, , , , , , , , & show all
Article: FSO332 | Received 24 Apr 2018, Accepted 27 Jun 2018, Published online: 24 Aug 2018

References

  • Preterm birth, World Health Organisation [www.who.int/mediacentre/factsheets/fs363/en/].
  • Fortunato SJ, Menon R, Lombardi SJ. MMP/TIMP imbalance in amniotic fluid during PROM: an indirect support for endogenous pathway to membrane rupture. J. Perinat. Med. 27, 362–368 (1999).
  • Ota A, Yonemoto H, Someya A, Itoh S, Kinoshita K, Nagaoka I. Changes in matrix metalloproteinase 2 activities in amniochorions during premature rupture of membranes. J. Soc. Gynecol. Investig. 13, 592–597 (2006).
  • Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase MMP-2 and MMP-9 in cancer, e.g. acute leukemia. Crit. Rev. Oncol. Hematol. 50, 87–100 (2004).
  • Rother S, Samsonov SA, Hofmann T et al. Structural and functional insights into the interaction of sulfated glycosaminoglycans with tissue inhibitor of metalloproteinase-3: a possible regulatory role on extracellular matrix homeostasis. Acta Biomater. 45, 143–154 (2016).
  • Wu J, Han W, Chen X, Guo W et al. Matrix metalloproteinase-2 and -9 contribute to functional integrity and noiseinduced damage to the blood-labyrinth-barrier. Mol. Med. Rep. 16, 1731–8 (2017).
  • DeLeon-Pennell KY, Meschiari CA, Jung M, Lindsey ML. Matrix metalloproteinases in myocardial infarction and heart failure. Prog. Mol. Biol. Transl. Sci. 147, 75–100 (2017).
  • Amar S, Smith L, Fields GB. Matrix metalloproteinase collagenolysis in health and disease. Biochim. Biophys. Acta 1864(11 Pt A), 1940–1951 (2017).
  • Liu J, Khalil RA. Matrix metalloproteinase inhibitors as investigational and therapeutic tools in unrestrained tissue remodeling and pathological disorders. Prog. Mol. Biol. Transl. Sci. 148, 355–420 (2017).
  • Itoh Y. Metalloproteinases in rheumatoid arthritis: potential therapeutic targets to improve current therapies. Prog. Mol. Biol. Transl. Sci. 148, 327–338 (2017).
  • Chen J, Khalil RA. Matrix metalloproteinases in normal pregnancy and preeclampsia. Prog. Mol. Biol. Transl. Sci. 148, 87–165 (2017).
  • Rahimi Z, Abdan Z, Rahimi Z et al. Functional promoter polymorphisms of MMP-2 C-735T and MMP-9 C-1562T and their synergism with MMP-7 A-181G in multiple sclerosis. Immunol. Invest. 45, 543–552 (2016).
  • Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog. Mol. Biol. Transl. Sci. 147, 1–73 (2017).
  • Dang B, Shen H, Li H, Zhu M, Guo C, He W. Matrix metalloproteinase 9 may be involved in contraction of vascular smooth muscle cells in an in vitro rat model of subarachnoid hemorrhage. Mol. Med. Rep. 14, 4279–4284 (2016).
  • Ziani L, Safta-Saadoun TB, Gourbeix J et al. Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion. Oncotarget 8, 19780–19794 (2017).
  • Mercer BM. Preterm premature rupture of the membranes: current approaches to evaluation and management. Obstet. Gynecol. Clin. North Am. 32, 411 (2005).
  • Herouy Y. The role of matrix metalloproteinases (MMPs) and their inhibitors in venous leg ulcer healing. Phlebolymphology 44, 231–243 (2004).
  • Locksmith GJ, Clark P, Duff P, Saade GR, Schultz GS. Amniotic fluid concentrations of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during pregnancy and labor. Am. J. Obstet. Gynecol. 184, 159–164 (2001).
  • Athayde N, Edwin SS, Romero R et al. A role for matrix metalloproteinase-9 in spontaneous rupture of the fetal membranes. Am. J. Obstet. Gynecol. 179, 1248–1253 (1998).
  • Romero R, Chaiworapongsa T, Espinoza J et al. Fetal plasma MMP-9 concentrations are elevated in preterm premature rupture of the membranes. Am. J. Obstet. Gynecol. 187, 1125–1130 (2002).
  • Zuo G, Dong JX, Zhao FF, Chen Y. Expression of matrix metalloproteinase-9 and its substrate level in patients with premature rupture of membranes. J. Obstet. Gynaecol. 37, 441–445 (2017).
  • Sukhikh GT, Kan NE, Tyutyunnik VL, Sannikova MV, Dubova EA, Pavlov KA. The role of extracellular inducer of matrix metalloproteinases in premature rupture of membranes. J. Matern. Fetal Neonatal Med. 29, 656–659 (2016).
  • Zhang G, Feenstra B, Bacelis J et al. Genetic associations with gestational duration and spontaneous preterm birth. N. Engl. J. Med. 377, 1156–1167 (2017).